Carl's Jr. is teaming up with Monster Energy to introduce Star Energy, a new lineup of beverages featuring Monster Zero Ultra ...
Disc Medicine anticipates a U.S. Food and Drug Administration decision on bitopertin by mid-2027, with a potential launch ...
Drip Gym, a New York-based medical IV therapy provider offering physician-reviewed iron infusion services, announced today the nationwide rollout of its at-home IV iron infusion service across all 50 ...
Fennec Pharmaceuticals (NASDAQ:FENC) reported third-quarter net product sales of $19.4 million, up 56% from a year earlier, ...
PepGen is rated a Buy, after phase 2 DM1 data show 46.5% mean splicing correction, supporting a potential FDA meeting in 2H ...
Science Focus on MSN
'Escalating threat': A deadly fungus no standard drug can treat could be spreading undetected, warn experts
Scientists have found a fungus no standard drug can treat – and there are likely more cases out there ...
ChronicleBio, an AI-driven precision therapeutics company focused on chronic neuroimmune diseases, and Prolong ...
A two-center retrospective study of pediatric hemodialysis patients found no statistically detectable difference in six-month ...
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that ...
Good morning, ladies and gentlemen, and welcome to the Fennec Pharmaceuticals Third Quarter 2026 Earnings and Corporate Update Conference Call. [Operator Instructions] As a reminder, today's ...
An all-oral regimen is a meaningful advance in newly diagnosed AML, yet early monitoring needs, complex dosing, and patient readiness lead many clinicians to begin cycle 1 intravenously.
A multimodal regimen combining targeted oral inhibitors with intrathecal chemotherapy achieved complete remission and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results